AAAAAA

   
Results: 1-10 |
Results: 10
In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects
Authors: Ramanathan, M Weinstock-Guttman, B Nguyen, LT Badgett, D Miller, C Patrick, K Brownscheidle, C Jacobs, L
Citation: M. Ramanathan et al., In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects, J NEUROIMM, 116(2), 2001, pp. 213-219
Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS
Authors: Rudick, RA Cutter, G Baier, M Fisher, E Dougherty, D Weinstock-Guttman, B Mass, MK Miller, D Simonian, NA
Citation: Ra. Rudick et al., Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS, NEUROLOGY, 56(10), 2001, pp. 1324-1330
Multiple sclerosis: Experience with large clinical trials
Authors: Cookfair, DL Weinstock-Guttman, B Cohen, JA
Citation: Dl. Cookfair et al., Multiple sclerosis: Experience with large clinical trials, CLINICAL TRIALS IN NEUROLOGY, 2001, pp. 387-402
Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients
Authors: Fisher, E Rudick, RA Cutter, G Baier, M Miller, D Weinstock-Guttman, B Mass, MK Dougherty, DS Simonian, NA
Citation: E. Fisher et al., Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients, MULT SCLER, 6(6), 2000, pp. 373-377
Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25)
Authors: Balcer, LJ Baier, ML Kunkle, AM Rudick, RA Weinstock-Guttman, B Simonian, N Galetta, SL Cutter, GR Maguire, MG
Citation: Lj. Balcer et al., Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25), MULT SCLER, 6(6), 2000, pp. 382-385
A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations
Authors: Miller, DM Weinstock-Guttman, B Bethoux, F Lee, JC Beck, G Block, V Durelli, L LaMantia, L Barnes, D Sellebjerg, F Rudick, RA
Citation: Dm. Miller et al., A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations, MULT SCLER, 6(4), 2000, pp. 267-273
Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAS in peripheral blood mononuclear cells using DNA arrays
Authors: Nguyen, LT Ramanathan, M Weinstock-Guttman, B Dole, K Miller, C Planter, M Patrick, K Brownscheidle, C Jacobs, LD
Citation: Lt. Nguyen et al., Detection of cytochrome P450 and other drug-metabolizing enzyme mRNAS in peripheral blood mononuclear cells using DNA arrays, DRUG META D, 28(8), 2000, pp. 987-993
What is new in the treatment of multiple sclerosis?
Authors: Weinstock-Guttman, B Jacobs, LD
Citation: B. Weinstock-guttman et Ld. Jacobs, What is new in the treatment of multiple sclerosis?, DRUGS, 59(3), 2000, pp. 401-410
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (R) (IFN beta-1a) for relapsing multiple sclerosis
Authors: Rudick, RA Cookfair, DL Simonian, NA Ransohoff, RM Richert, JR Jacobs, LD Herndon, RM Salazar, AM Fischer, JS Granger, CV Goodkin, DE Simon, JH Bartoszak, DM Bourdette, DN Braiman, J Brownscheidle, CM Coats, ME Cohan, SL Dougherty, DS Kinkel, RP Mass, MK Munchsauer, FE O'Reilly, K Priore, RL Pullicino, PM Scherokman, BJ Wende, K Weinstock-Guttman, B Whitham, RH
Citation: Ra. Rudick et al., Cerebrospinal fluid abnormalities in a phase III trial of Avonex (R) (IFN beta-1a) for relapsing multiple sclerosis, J NEUROIMM, 93(1-2), 1999, pp. 8-14
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials
Authors: Goodkin, DE Priore, RL Wende, KE Campion, M Bourdette, DN Herndon, RM Fischer, JS Jacobs, LD Cookfair, DL Rudick, RA Richert, JR Salazar, AM Granger, CV Simon, JH Alam, JJ Bartoszak, DM Braiman, J Brownscheidle, CM Coats, ME Cohan, SL Dougherty, DS Kinkel, RP Mass, MK Munschauer, FE Pullicino, PM Scherokman, BJ Weinstock-Guttman, B Whitham, RH
Citation: De. Goodkin et al., Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials, MULT SCLER, 4(6), 1998, pp. 480-486
Risultati: 1-10 |